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Attention deficit hyperactivity disorder (ADHD) is a clinical disorder characterized
by persistent hyperactivity, inattention, and impulsivity.1 Symptoms appear to be
developmentally inappropriate and lead to functional impairments at home or in
school.2 Children with ADHD are more likely to have comorbid learning difficulties
and behavioral problems, and to have poor peer relationships and low self-
esteem.3 About 30-50% of children with ADHD have significant behavior and
psychiatric problems in adulthood.4-6 Persistence of ADHD symptoms into
adolescence and adulthood is associated with antisocial behavior, substance use
and abuse,7 fewer years of education, and lower rates of employment.8
Symptom control is strongly related to functional improvement.9-11 Methyl-
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Purpose: Methylphenidate (MPH) is an effective medication for the treatment of attention deficit hyperactivity
disorder (ADHD). However, about 30% of patients do not respond to or are unable to tolerate MPH. Based on
previous findings, we hypothesized that great variability in response time (RT) among Korean children with ADHD
on a computerized continuous performance attention test would be related to poor MPH treatment response.
Materials and Methods: Children (ages 6-18 years) with ADHD were recruited for a prospective 12-week, open-
labeled, multicenter study to examine optimal dosage of OROS methylphenidate. Of the 144 subjects selected, 28
dropped out due to adverse events, medication noncompliance, or follow-up loss, and an additional 26 subjects with
comorbid disorders were excluded from statistical analyses. We defined ‘responders’ as subjects who received a
score of less than 18 on the attention deficit hyperactivity disorder rating scale (ARS; Korean version, K-ARS) and
a score of 1 or 2 on the Clinical Global Impression-Improvement scale (CGI-I). RT variability was assessed with
the ADHD diagnostic system (ADS). Results: Fifty-nine (67%) subjects responded to MPH treatment. The non-
responders showed greater RT variability at baseline (Mann Whitney U = 577.0, p < 0.01). Baseline RT variability
was a significant predictor of MPH response (Nagelkerke R2 = 0.136, p < 0.01). It predicted 94.9% of responder,
17.2% of non-responder and 69.3% of overall group. Conclusion: High RT variability may predict poor response
to MPH treatment in children with ADHD.
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INTRODUCTION
phenidate (MPH) is recommended for the treatment of
ADHD.12 Studies indicate that MPH is an effective remedy
for both core symptoms (e.g., inattention, hyperactivity, and
impulsivity) and aggressive behavior.13 MPH increases
child compliance with parental commands and decreases
hostile and negative responses, which facilitates the social
interactions in young children.14-16 However, about 30% of
children with ADHD do not tolerate or respond to stimulant
medication.17,18 A study reported that the electroencephalo-
gram (EEG) patterns of children who respond to MPH
treatment are different from those who do not respond.19
However, little else is known regarding predictive factors
for responsiveness to MPH. Further research into these
predictive factors is warranted.
Studies have consistently shown that great response time
(RT) variability is found in children with ADHD, making
it a potential marker for differentiating children with
ADHD from those without ADHD.20-26 Homozygosity for
the DAT 10-repeat allele is correlated with poor response
to MPH treatment among Korean children with ADHD.27
Furthermore, ADHD patients who have two copies of the
10-repeat allele at the dopamine transporter gene (DAT)
show greater variability in RT on attention tests compared
to those with fewer than two copies.28 These data suggest
the possible relationship between greater RT and poor
response to MPH treatment. We performed this study to
examine whether great RT variability would be predictive
of poor response to MPH treatment in children with ADHD. 
Participants
Participants were recruited from seven sites in Korea for a
prospective 12-week, open-labeled study to examine opti-
mal dosage of OROS methylphenidate. Diagnoses were
made with the Kiddie-Schedule for Affective Disorders
and Schizophrenia-Present and Lifetime Version (K-
SADS-PL).29 Exclusion criteria were as follows: use of
MPH hydrochloride other than OROS-MPH within the
past 24 hours; use of OROS-MPH within the past three
months; use of psychotropic medication within the past
four months (clonidine or other α-adrenaline agonist,
tricyclic antidepressant, selective serotonin reuptake inhi-
bitor, theophylline, coumarin, or anticonvulsant, antipsy-
chotics, benzodiazepine, modafinil); history of hypersensi-
tivity reaction to MPH hydrochloride or another component
of OROS MPH; other medical problems, such as gastroin-
testinal disorders, glaucoma, cardiovascular disease, or
hyperthyroidism; neurological illnesses, such as a seizure
disorder; comorbid psychiatric disorders, such as pervasive
development disorder, psychotic disorder, or Tourette
syndrome; an intelligence quotient (IQ) less than 70 [as
assessed by the Korean Wechsler Intelligence Scale for
Children (K-WISC-III)30]; history of substance use or
abuse; and possible pregnancy. After an initial assessment,
144 subjects (ages 6-18 years) with ADHD were included.
Baseline MPH dosages were either 18 mg or 27 mg
depending on clinical judgment. Dosage was titrated for
nine weeks, at which point it was maintained for the rema-
inder of the 12-week treatment trial. Of the 144 subjects
enrolled in the study, 28 dropped out due to adverse events
(n = 8, 28.6%), medication noncompliance (n = 12, 42.9%),
or follow-up loss (n = 6, 21.4%). Data from an additional
24 subjects with comorbid disorders, such as oppositional
defiant disorder (n = 12), tic disorder (n = 9), depressive
disorder (n = 3), and anxiety disorder (n = 6), were excluded.
Since the ADHD diagnostics system was standardized for
children of 6-15 years, we excluded 2 subjects who were
older than 15. Thus, data from 88 participants were
included in the final statistical analyses. 
This study was approved by the Institutional Review
Boards of all seven sites.
Measures 
Symptom severity and treatment effectiveness
The attention deficit hyperactivity disorder rating scale
(ARS; Korean version, K-ARS) is an 18-item measure
used to assess inattention and hyperactivity. Items are rated
on a 4-point scale (0 = never or rarely, 3 = very often). The
K-ARS has good reliability and validity among Korean
children.31 The IOWA Conners Parent Rating Scale (CPRS)
is a 10-item measure administered to parents to assess
inattention/overactivity (5 items) and oppositional/defiant
behavior (5 items) in children.32 The CPRS has a 4-point
rating scale (0 = never, 3 = very often) and it has good
reliability and validity.32 The Clinical Global Impression
Severity (CGI-S) and Clinical Global Impression Improve-
ment (CGI-I) scales are clinical outcome measures. Both
are clinician-administered and consist of 7-point scales (1
= much improved, 7 = much worse). Generally, the CGI-I
is more sensitive to treatment effect.33 We defined ‘respon-
ders’ as subjects who received a score of less than 18 on
the K-ARS and a score of 1 or 2 on the CGI-I, and ultimately
were in remission state.34 Clinical assessment was done at
baseline as well as weeks 1, 3, 6, 9, and 12. Body weights
and vital signs were measured at every visit. ECG and
laboratory measures were assessed at baseline and week 12. 
ADHD diagnostic system
The ADHD diagnostic system (ADS) is a computerized
continuous performance test that consists of auditory and
visual modalities.35 In each modality, the targets and non-
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MATERIALS AND METHODS
targets are presented in the form of auditory or visual stimuli.
The test can be used to assess children over five years of
age. It consists of three sessions: the early, middle, and late
phases. The ADS generates four broadband scores. The
omission errors score indicates the number of times when
the subject failed to respond to the target, with high scores
reflecting inattention. The commission errors score indicates
the number of times when the subject made an incorrect
response to the non-target, with high scores reflecting
impulsivity. The response time (RT) score measures the
amount of time between presentation of the target stimulus
and a correct response. RT is related to speed of information
processing and motor response. The standard deviation of
the RT reflects variability or consistency of attention.35
Scores are reported as T-scores and  produced in a printable
report. In our study, each subject performed the ADS at
baseline and at the end of the study. We used scores derived
from the visual modality of the ADS in light of research
suggesting that the auditory modality is more difficult than
the visual modality and is less sensitive in differentiating
subjects with ADHD from healthy controls.35
Statistical analyses
To examine the effect of the RT variability on the MPH
treatment response, we carried out analysis in two phases.
At the first phase, we conducted T-tests, chi-square tests,
Mann-Whitney U tests and univariate analysis of variance
(ANOVA) to determine whether the responders differed
significantly from the non-responders on the focal variables
and extract the predictor variables. The RT variability was
entered as an independent variable and commission error
score was entered as a covariate for univariate ANOVA.
Secondly, to examine the effect of the baseline RT variabi-
lity on the MPH response, we conducted a binary logistic
regression analysis, with baseline RT variability entered as
the predictor variable, and “responder/non-responder” as
the dependent variable. We ran a series of paired T-tests to
compare the baseline and 12 week ADS scores. We then
computed correlations to examine the relationship between
the ADS scores and the behavior rating scale scores. 
The mean age of the participants at baseline was 9.43 years
(± 2.2). Slightly more than 87.5% (n = 77) of the children
were boys and 11 (12.5%) were girls. The average IQ was
109.7 (± 16.1). The mean K-ARS and CPRS scores were
28.2 (± 8.5) and 11.7 (± 5.3), respectively. 
Characteristics of the responders (n = 59) and non-
responders (n = 29) are shown in Table 1. There were no
significant differences between the responders and non-
responders for age or gender. Nor were there any signifi-
cant differences between the responders and non-respon-
ders for baseline IQ, K-ARS, and CPRS scores. 
At week 12, the mean dosage of MPH across subjects
was 0.99 mg/kg (± 0.29). There was no statistically signi-
ficant difference in week 12 MPH dosage between the res-
ponders and non-responders. At week 12, the responders
scored significantly lower on the K-ARS and CPRS com-
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RESULTS
Table 1. Characteristics of the Responders and Non-Responders
Responders Non-responders
t-score p value
(n = 59) (n = 29)
Age 9.1(± 2.2) 9.6 (± 2.2) 0.888 NS
Sex
Girl 9 2 1.242* NS�
Boy 50 27
IQ 109.7 (± 14.5) 109.1 (± 15.0) -0.478 NS
K-ARS
Baseline 27.4 (± 8.0) 30.0 (± 9.2) 1.379 NS
At 12 weeks 9.3 (± 4.3) 17.4 (± 8.9) 371.5� < 0.01
CPRS 
Baseline 11.4 (± 4.6) 12.5 (± 6.6) 785.5� NS
At 12 weeks 4.6 (± 3.0) 8.5 (± 4.6) 426.5� < 0.01
Dosage at 12 weeks (mg/Kg) 1.0 (± 0.3) 0.9 (± 0.2) -1.125 NS
IQ, Intelligence quotient, as assessed by the Korean Wechsler Intelligence Scale for Children (K-WISC-III); K-ARS, Korean version of the 
ADHD Rating Scale; CPRS, IOWA Conners Parent Rating Scale.
Numbers are means (± standard deviations), except for sex, where numbers represent frequencies.
*χ2.  
�Fisher’s exact test.
�Mann-Whitney U.
pared to the non-responders (Table 1). 
The ADS scores are summarized in Table 2. At baseline,
the result of univariate ANOVA showed that the non-
responders had significantly greater RT variability com-
pared to the responders (F = 5.330, p = 0.028). However,
there was no significant difference in commission error
between responders and non-responders. The non-responder
RT variability at week 12 was 78.0 (± 39.5), which is out
of normal range and has clinical significance.35
There was a significant decrease in commission errors
and RT variability from baseline to week 12 among the
responders (Fig. 1). The means of all four scores fell
within the normal range. Similarly, there was a significant
decrease in commission errors and RT variability from
baseline to week 12 among the non-responders (Fig. 2).
However, among the non-responders, RT variability was
greater than 70 even after 12 weeks of treatment. 
The ADS scores were not correlated with the K-ARS
and CPRS scores at baseline or at week 12.
RT variability at baseline was a significant predictor of
treatment response at week 12 (Nagelkerke R2 = 0.136, p <
0.01). It predicted 94.9% of responder, 17.2% of non-
responder and 69.3% of overall group. 
In the present study, the non-responders showed greater
RT variability at baseline. Great RT variability may reflect
dysfunctional prefrontal activity and inefficient top-down
control of attention.36 In a longitudinal study to evaluate the
neuropsychological functions of children with ADHD,
Halperin, et al.37 reported that a deficiency in response varia-
bility remained at the 10-year follow-up regardless of
remission status. Great RT variability seems to indicate
high risk in terms of the persistence of deficit in ADHD.
Our results together, with those of earlier studies20,37 suggest
that patients with great RT variability may have more
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Fig. 1. ADHD diagnostic system scores of the responders. Baseline and week
12 scores were compared by paired T-test analyses. ADHD, attention deficit
hyperactivity disorder. *p < 0.05, �p < 0.01.
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Fig. 2. ADHD diagnostic system scores of the non-responders. Comparison of
baseline and week 12 scores were made by paired T-test analyses. ADHD,
attention deficit hyperactivity disorder.  *p < 0.05.
Table 2. ADHD Diagnostic System (ADS) Scores of the Responders and Non-Responders at Baseline and Week 12
Responders Non-responders
t-score p value
(n = 59) (n = 29)
Baseline
Omission 68.3 (± 42.3) 71.3 (± 24.6) 0.351 NS
Commission 65.8 (± 26.7) 79.0 (± 37.6) 684.0* NS
Response time 54.1 (± 15.8) 57.3 (± 13.6) 0.935 NS
Variability 70.6 (± 25.5) 97.1 (± 53.4) 575.0* < 0.01
Week 12
Omission 56.8 (± 42.8) 60.1 (± 30.8) 0.373 NS
Commission 53.4 (± 20.4) 65.1 (± 33.4) 706.5* NS
Response time 50.6 (± 15.2) 52.8 (± 13.0) 0.666 NS
Variability 61.8 (± 25.1) 78.0 (± 39.5) 631.0* NS
Numbers are means (± standard deviations).
*Mann-Whitney U.
severe neuronal dysfunction and high RT may indicate poor
outcome. 
We found no significant correlations between RT varia-
bility and the K-ARS and CPRS scores, which is in line
with previous study, indicating that scores on continuous
performance tests have low correlations with ADHD
clinical symptom severity.38 In spite of the significant differ-
ence in baseline RT variability between the responders and
non-responders, there was no significant difference in
baseline clinical symptom severity between the responders
and non-responders. This suggests that MPH treatment
responsiveness is independent of baseline clinical symptom
severity. Furthermore, regardless of the responsiveness to
treatment, we found significant decreases in commission
and RT variability after treatment. This also supports
previous finding to show low correlation between clinical
symptoms and CPT test results.
It is generally accepted that MPH can decrease the errors
of omission.39 In the present study, there was a tendency to
decrease in the errors of omission after treatment, however
it did not reach statistical significance. Small sample size
would be a possible explanation.
To our best knowledge, we are the first to present find-
ings to indicate that great RT variability may predict poor
response to MPH treatment. Although Coghill, et al.40 exa-
mined whether baseline neuropsychological functioning
predicted clinical response to MPH, they did not include a
measure of RT, therefore, their results could not be com-
pared to ours. 
This study has several limitations that should be noted.
First, a placebo control group was not included in the study
design. Second, we did not perform a time series analysis.
Since ADS program only preserves summary data and
converts T scores after completion of the task, we were
unable to collect response time from each response. Studies
using time series analyses of RT data suggest that RT
variability can be broken down into heterogeneous compo-
nents.21,25 In a time series analysis of data gathered from a
Sustained Attention to Response Task (SART), Johnson,
et al.41 reported that RT variability has ‘fast’ and ‘slow’
components, and that the fast component of RT variability
reflects moment-to-moment variability and is predictive of
response to MPH treatment, whereas the slow component
of RT variability reflects a gradual deterioration in RT
variability and is not predictive of response to MPH treat-
ment. They also found no significant difference between
the subjects with ADHD and the healthy controls in slow
variability RT, suggesting that this component of RT may
not tap into the deficits associated with ADHD. We were
unable to compare our findings with those of Johnson, et
al., as we used a different measure of RT variability, but
future research to determine the predictive powers of the
fast and slow components of RT variability is needed
using a time series analysis. Third, the worst responders
might have been dropped out due to lack of compliance.
The effect was still found, nevertheless, the effect seen in
this study might be underestimated.
In spite of these limitations, the present study has impli-
cations for clinical work. Our finding to suggest that RT
variability may be predictive of MPH treatment response
provides clinicians with a possible clinical indicator to be
used in treatment planning with MPH.
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